NEUREN PHARMACEUTICALS LIMITED (NEU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NEU

NEU - NEUREN PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$19.75

05 Dec
2025

0.670

OPEN

$19.14

3.51%

HIGH

$19.81

199,363

LOW

$19.10

TARGET
$25.70 30.1% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
NEU: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 111.2 14.3 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx - 10.1% - 87.1% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 138.1 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx111.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx213.2 M
Book Value Per Share xxxxxxxxxxxxxxx286.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-11.3 M
Net Profit Margin xxxxxxxxxxxxxxx66.61 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx49.92 %
Return on Invested Capital xxxxxxxxxxxxxxx49.92 %
Return on Assets xxxxxxxxxxxxxxx43.20 %
Return on Equity xxxxxxxxxxxxxxx49.92 %
Return on Total Capital xxxxxxxxxxxxxxx61.70 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-11.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx222 M
Price To Book Value xxxxxxxxxxxxxxx4.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.00 %
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx38 M
Research & Development xxxxxxxxxxxxxxx33 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

07/11/2025

1

Buy

$25.00

26.58%

Neuren Pharmaceuticals’ commercial partner Acadia Pharmaceuticals reported US$101m in Daybue sales in 3Q25, up 11% y/y and 5% q/q, broadly in line with expectations.

Bell Potter notes FY25 sales guidance was narrowed to US$385-400m, with growth driven purely by volume. Neuren earned $45m in royalties in nine months, with the broker forecasting $64m for FY25 on US$390m Daybue sales.

The broker notes patient persistence remains strong (over 50% at 12 months), and upcoming catalysts include EU approval, targeted for Jan 2026 and first sales in 2Q26.

Forecasts largely unchanged, with the broker expecting the company to post another profitable FY25 result.

Buy. Target unchanged at $25.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 13.70 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 32.20 cents.

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

06/11/2025

1

Buy

$23.00

16.46%

Neuren Pharmaceuticals' licensing partner for Daybue, Acadia Pharmaceuticals, revealed 3Q sales of US$101.1m, broadly in line with Canaccord Genuity's expectations. FY25 revenue guidance was narrowed to US$385-400m.

This implies to the broker Neuren’s 2025 royalty income of $63-66m remains on track, supported by expanding patient numbers and stronger uptake outside centres of excellence.

Market share in community settings has risen to 27% from 20%, reflecting the impact of Acadia’s enlarged salesforce, explain the analysts.

Canaccord sees further upside from European Medicines Agency (EMA) approval in early 2026 and ongoing phase 3 programs.

The broker retains a Buy rating and $23 target.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 17.00 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 61.00 cents.
Access Extra Coverage Research History >

NEU STOCK CHART

FNArena News on NEU

1
Australian Broker Call *Extra* Edition – Nov 12, 2025

Nov 12 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Nov 10, 2025

Nov 10 2025 - Daily Market Reports
3
Rudi’s View: Catalyst Metals, Dexus, Neuren, Stockland, ResMed & More

Sep 04 2025 - Rudi's View
4
Australian Broker Call *Extra* Edition – Sep 03, 2025

Sep 03 2025 - Daily Market Reports
5
FNArena Corporate Results Monitor – 28-08-2025

Aug 28 2025 - Australia

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
2
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
3
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
4
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
5
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
6
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
7
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
8
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
9
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
10
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia